Intravenous Hemostat: Nanotechnology to Halt Bleeding
| dc.contributor.author | Bertram, James P. | |
| dc.contributor.author | Williams, Cicely A. | |
| dc.contributor.author | Robinson, Rebecca | |
| dc.contributor.author | Segal, Steven S. | |
| dc.contributor.author | Flynn, Nolan T. | |
| dc.contributor.author | Lavik, Erin | |
| dc.date.accessioned | 2021-03-19T17:55:52Z | |
| dc.date.available | 2021-03-19T17:55:52Z | |
| dc.date.issued | 2009-12-16 | |
| dc.description.abstract | Blood loss is the major cause of death in both civilian and battlefield traumas. Methods to staunch bleeding include pressure dressings and absorbent materials. For example, QuikClot effectively halts bleeding by absorbing large quantities of fluid and concentrating platelets to augment clotting, but these treatments are limited to compressible and exposed wounds. An ideal treatment would halt bleeding only at the injury site, be stable at room temperature, be administered easily, and work effectively for internal injuries. We have developed synthetic platelets based on Arg-Gly-Asp functionalized nanoparticles, which halve bleeding time after intravenous administration in a rat model of major trauma. The effects of these synthetic platelets surpass other treatments, including recombinant factor VIIa, which is used clinically for uncontrolled bleeding. Synthetic platelets were cleared within 24 hours at a dose of 20 mg/ml, and no complications were seen out to 7 days after infusion, the longest time point studied. These synthetic platelets may be useful for early intervention in trauma and demonstrate the role that nanotechnology can have in addressing unmet medical needs. | en_US |
| dc.description.sponsorship | : J.P.B. partially supported by the Coulter Foundation (Early Career Award to E.B.L.) and Richard and Gail Siegal. J.P.B. and R.R. partially supported by NIH Neuroengineering training grant T90-DK070068. C.A.W. partially supported by NIH MSTP training grant 5T32GM07025. C.A.W. and R.R. partially supported by Richard and Gail Siegal and Carol Sirot. S.S.S. supported by NIH grants HL56786 and HL41026. | en_US |
| dc.description.uri | https://stm.sciencemag.org/content/1/11/11ra22 | en_US |
| dc.format.extent | 17 pages | en_US |
| dc.genre | journal articles postprints | en_US |
| dc.identifier | doi:10.13016/m2euhc-rrfq | |
| dc.identifier.citation | JAMES P. BERTRAM, CICELY A. WILLIAMS, REBECCA ROBINSON, STEVEN S. SEGAL, NOLAN T. FLYNN, ERIN B. LAVIK, Intravenous Hemostat: Nanotechnology to Halt Bleeding, Science Translational Medicine, Vol. 1, Issue 11, pp. 11ra22 DOI: 10.1126/scitranslmed.3000397 | en_US |
| dc.identifier.uri | https://doi.org/10.1126/scitranslmed.3000397 | |
| dc.identifier.uri | http://hdl.handle.net/11603/21199 | |
| dc.language.iso | en_US | en_US |
| dc.publisher | AAAS | en_US |
| dc.relation.isAvailableAt | The University of Maryland, Baltimore County (UMBC) | |
| dc.relation.ispartof | UMBC Chemical, Biochemical & Environmental Engineering Department Collection | |
| dc.rights | This item is likely protected under Title 17 of the U.S. Copyright Law. Unless on a Creative Commons license, for uses protected by Copyright Law, contact the copyright holder or the author. | |
| dc.rights | This is the author’s version of the work. It is posted here by permission of the AAAS for personal use, not for redistribution. The definitive version was published in Science Translational Medicine on Vol 1, Issue 11, 16 December 2009, DOI: 10.1126/scitranslmed.3000397. | |
| dc.title | Intravenous Hemostat: Nanotechnology to Halt Bleeding | en_US |
| dc.type | Text | en_US |